Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Research Australia
GroPep is awarded a key patent for infertility treatment in Europe
August 18th, 2006
Adelaide biotechnology company, GroPep, has achieved a major development milestone in its infertility drug program with the granting of European patent number 1028743, which covers GroPep's drug for the treatment of recurrent miscarriage. The patent provides the company with a European market patent exclusivity until at least 2018. GroPep already has two U.S. patents covering the active ingredient of the drug until 2020. According to the American College of Obstetricians and Gynecologists, at least 50% of recurrent miscarriages have no apparent explanation and there is no cure. The size of the market, the lack of competition and the strong patent...
Source: Biotech Law Weekly (2006-08-18)
|
